Nothing said here yet.
to join the conversation.
ArriVent BioPharma (NASDAQ:AVBP) presented Phase I data for ARR-217, its CDH17-targeting antibody-drug conjugate, or ADC, in heavily pretreated metastatic colorectal cancer patients during a virtual webinar following an ESMO late-breaking oral presentation.
ArriVent BioPharma (AVBP) is back in focus after releasing initial Phase 1 data for its CDH17-targeted antibody drug conjugate ARR-217 at the 2026 ESMO Congress and advancing the asset into Phase 1b.
ArriVent BioPharma disclosed that its global Phase 3 FURVENT trial did not meet its primary endpoint, prompting a law firm to investigate whether prior disclosures around the trial and emerging efficacy data adequately informed investors.
ArriVent BioPharma shares lost more than half their value after the pivotal Phase 3 FURVENT trial of lead candidate firmonertinib missed its primary endpoint. An investigation into potential securities law violations is underway on behalf of AVBP investors.
AVBP was down 56.7% before the opening bell and traded as low as $12.09 after ArriVent disclosed that its Phase 3 FURVENT trial of firmonertinib missed its primary endpoint. An investigation into potential securities law violations is underway. NEW YORK, Oct.
ArriVent’s disappointing data comes just weeks after J&J had a successful readout in the same NSCLC patient population.
AVBP shareholders are holding stock near a $12.09 52-week low after the Phase 3 FURVENT trial missed its primary endpoint, just five months after ArriVent launched a $250 million at-the-market stock offering. NEW YORK, Oct.
ArriVent BioPharma Inc. (NASDAQ:AVBP) stock fell on Tuesday with a session volume of 14.10 million compared to the average volume of 524.163 thousand, according to Benzinga Pro data.